Abstract
Dupilumab is a fully humanized monoclonal antibody targeting the interleukin (IL)-4Rα subunit of the IL-4 and IL-13 receptors. IL-4 and IL-13 are type 2 cytokines involved in the pathogenesis of atopic dermatitis (AD) and allergic diseases including asthma, food allergy, allergic rhinitis (AR), eosinophilic esophagitis (EoE), and chronic rhinosinusitis with nasal polyposis (CRwNP). Therefore, dupilumab has been hypothesized as a potential treatment for all of these atopic conditions,1, 2, 3 but is currently only approved by the US Food and Drug Administration for patients 6 years and older with moderate-to-severe AD, 12 years and older with moderate-to-severe asthma, and adults with CRwNP. It is not uncommon for AD patients to have a history of multiple allergic conditions; it is less common to have all of them coexisting (ie, active) concurrently.4, 5, 6 To our knowledge, this is the first case report of a pediatric AD patient with multiple comorbid allergic conditions who experienced objective improvements in all of his conditions (AD, EoE, asthma, AR, and chronic sinusitis [CS]) with dupilumab treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
